Long acting glucagon like polypeptide-1 (GLP-1) receptor agonists and methods of use
Inventors
Blackwell, William • Srivastava, Ved P. • Paulik, Mark
Assignees
Intarcia Assignment For Benefit Of Creditors LLC • I2O Therapeutics Inc
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
This invention relates to isolated polypeptides that are long acting analogs of human GLP-1. The disclosed GLP-1 receptor agonist polypeptides have beneficial physicochemical properties relative to endogenous GLP-1 and known synthetic GLP-1 receptor agonist polypeptides, such as longer (i.e., “long-acting”) elimination half-lives (t1/2), and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed GLP-1 receptor agonist polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed GLP-1 receptor agonist polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as type 2 diabetes, treating obesity, and providing weight loss, and in methods of treating nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).
Core Innovation
The invention provides long-acting GLP-1 receptor agonist isolated polypeptides defined as human GLP-1 analogs with a position-variable amino-acid sequence and terminal and internal sequence segments as described in the SEQ ID NOs. The polypeptides are disclosed as isolated sequences or pharmaceutically acceptable salts, including exemplified sequences identified by SEQ ID NO: 1115, 1120, 1132, and SEQ ID NO: 200.
The polypeptides include conditional structural features based on the identity at position X16 and related covalent modifications. When X16 is Dab, Dap, K, or Orn, it is covalently bound to a lipophilic substituent, optionally via a spacer; when X16 is E, at least one of X17, X18, X19, X20, or X21 is K and covalently bound to a lipophilic substituent, optionally via a spacer.
The polypeptides further optionally comprise a lactam bridge formed via an amide bond between the side chains of K and E at selected position pairs among X17 and X21, X21 and X17, X21 and X28, X28 and X21, X20 and X24, X24 and X20, or X12 and X16. The disclosure also includes pharmaceutically acceptable salts, exemplified by acetate, trifluoroacetic acid (TFA), and hydrochloride (HCl) salts.
Claims Coverage
The claim coverage centers on an isolated GLP-1 receptor agonist polypeptide defined by a position-variable amino-acid sequence, with conditional covalent lipophilic substitution and an optional K/E lactam-bridge feature. The independent-claim material also includes a pharmaceutical composition and a method for treating obesity in a human by administering that composition. Three inventive features are covered.
Position-variable isolated GLP-1 analog polypeptide sequence
An isolated polypeptide comprising the amino acid sequence HX2X3GTX6X7X8X9X10SX12X13X14EX16X17X18X19X20X21FIX24WLKX28GGPX32SGAPPPS-(OH/NH2), or a pharmaceutically acceptable salt thereof, wherein each X position is defined by allowed residue options.
Conditional covalent attachment of a lipophilic substituent at X16
When X16 is Dab, Dap, K, or Orn, X16 is covalently bound to a lipophilic substituent, optionally via a spacer; when X16 is E, at least one of X17, X18, X19, X20, or X21 is K and is covalently bound to a lipophilic substituent optionally via a spacer.
Optional K/E lactam bridge formed by an amide bond
The peptide optionally further comprises a lactam bridge formed via an amide bond between the side chains of K and E at selected position pairs among X17 and X21, X21 and X17, X21 and X28, X28 and X21, X20 and X24, X24 and X20, or X12 and X16.
The claim coverage centers on an isolated polypeptide defined by a position-variable sequence, with conditional covalent lipophilic substitution at X16 or at specified lysine positions when X16 is E, and an optional lactam bridge formed by an amide bond between side chains of K and E at specified position pairings, with additional coverage for a pharmaceutical composition and human obesity treatment.
Stated Advantages
Long elimination half-life (t1/2).
Improved solubility.
Thermal stability.
Documented Applications
GLP-1 receptor agonist treatment of metabolic diseases, including type 1 diabetes, type 2 diabetes, obesity, and NAFLD/NASH.
Obesity treatment in a human by administering a pharmaceutical composition containing the isolated polypeptide or a pharmaceutically acceptable salt, for weight loss or suppressing appetite.
Interested in licensing this patent?